局部受体相互作用蛋白激酶2抑制减轻室内灰尘引发的喘
Daniel Alvarez-Simon1, Saliha Ait Yahia1, Camille Audousset1
1Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d'Infection et d'Immunité de Lille, Lille, France.
The European respiratory journal
|August 8, 2024
概括
一种RIPK2抑制剂在小鼠模型中有效治疗室内灰尘引发的喘,特别是在人类化NOD1的小鼠中,这表明了过敏性喘的新治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 家庭灰尘虫 (HDM) 是过敏性喘的主要触发因素.
- 核酸结合的寡合化域1 (NOD1) /受体相互作用的氨酸/氨酸蛋白激酶2 (RIPK2) 途径与HDM诱导的喘有关.
- 这项研究研究了一种用于治疗喘的RIPK2抑制剂.
研究的目的:
- 为了评估局部RIPK2抑制剂在HDM诱导喘的小鼠模型中的有效性.
- 评估该抑制剂在野生型和人性化NOD1小鼠中的预防和治疗作用.
- 为了确定该抑制剂在人类喘患者衍生的上皮细胞培养中的相关性.
主要方法:
- 在小鼠高血压性喘模型中注射RIPK2抑制剂 (预防性和治疗性) 的鼻内注射.
- 评估呼吸道过敏反应,炎症,细胞因子/化学因子水平和粘液的产生.
- 在精密切割的肺切片和喘患者的空气-液体接口上皮质培养物上测试该抑制剂.
主要成果:
- 预防性RIPK2抑制减少了野生类型小鼠的喘症状;治疗性抑制效果较低,但减少了IL-33.
- 在人性化的NOD1小鼠中,治疗RIPK2抑制完全减轻了喘特征.
- 抑制剂降低了来自患者的细胞中的胸膜 stromal lymphopoietin 和化学激素的调节.
结论:
- 局部RIPK2抑制显示出作为一种新的治疗策略的承诺,用于家尘引发的喘.
- 通过RIPK2抑制准的NOD1信号通路是喘治疗的可行标.
- 研究结果强调了个性化医疗方法在喘治疗中的潜力.
相关概念视频
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
261
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
261
01:20Asthma: Pathogenesis and Management
378
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
378
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
271
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
271
01:17Drugs Used in Lower Respiratory Disorders: Overview
383
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
383
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K